Cancer biomarker discovery and translation: proteomics and beyond

Abstract

Introduction: Cancer is often diagnosed at late stages when the chance of cure is relatively low and although research initiatives in oncology discover many potential cancer biomarkers, few transition to clinical applications. This review addresses the current landscape of cancer biomarker discovery and translation with a focus on proteomics and beyond. Areas covered: The review examines proteomic and genomic techniques for cancer biomarker detection and outlines advantages and challenges of integrating multiple omics approaches to achieve optimal sensitivity and address tumor heterogeneity. This discussion is based on a systematic literature review and direct participation in translational studies. Expert commentary: Identifying aggressive cancers early on requires improved sensitivity and implementation of biomarkers representative of tumor heterogeneity. During the last decade of genomic and proteomic research, significant advancements have been made in next generation sequencing and mass spectrometry techniques. This in turn has led to a dramatic increase in identification of potential genomic and proteomic cancer biomarkers. However, limited successes have been shown with translation of these discoveries into clinical practice. We believe that the integration of these omics approaches is the most promising molecular tool for comprehensive cancer evaluation, early detection and transition to Precision Medicine in oncology.

Plasma Proteomics Analysis for Screening Anlotinib Responders in Non-small Cell Lung Cancer

“…Mark A Eckert et al suggested the metabolic regulator NNMT can be screened out via proteomics [21]. Furthermore, cancer biomarker screening based on proteomics has been introduced to clinical translational researches [19,22,23]. Due to complex architecture of anlotinib anti-angiogenic signaling pathway, proteomics can provide the platform just because of it can characterize proteins as a whole.…”

What Room for Two-Dimensional Gel-Based Proteomics in a Shotgun Proteomics World?

“…Consequently, many potential markers are identified and published but require further investigation. A comprehensive overview for challenges in biomarker discovery studies is given in e.g., [ 200 , 201 , 202 ].…”

Role of Proteomics in the Study of Trypanosoma cruzi Biology

“…From 1997, when the first paper on the proteome was published [7], proteomics studies have become an invaluable tool not only for the study of the global cell expression of proteins (the proteome) but also for the dissection of specific processes in cell biology and biochemistry, such as the study of proteins that are expressed in organelles and post-translational modifications [8,9]. Moreover, by combining proteomics analysis and bioinformatics tools, researchers can report much broader projections, including the identification of new chemotherapeutic targets, new vaccine candidates, new tumor markers with prognostic or diagnostic value [10], and the study of secretomes and immunonomes, among others [11]. Thus, a current PubMed search with the keyword "proteomic" delivers 96,688 published papers.…”